What is the official ID of this bill?
The official print number for this legislation is S 822.
Accelerating Rare Disease Drug Development: New Expert Meetings
This act aims to speed up the development of new drugs for rare diseases. It establishes regular meetings where experts, researchers, and patient representatives will collaborate to address challenges in the drug creation and approval process. This could mean faster access to much-needed treatments for individuals with rare conditions.
Key points
Establishes regular meetings for experts (scientists, doctors, patients, pharmaceutical companies) to discuss challenges in rare disease drug development.
Creates an advisory committee to select meeting topics, focusing on unmet medical needs and opportunities to accelerate research.
Requires public release of meeting summaries and recordings, increasing transparency and access to information.
Ensures input from these meetings is considered during drug approval, potentially shortening the time it takes for new treatments to reach patients.
Status:
Introduced
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.